Clinical implications of high NQO1 expression in breast cancers

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Yang, Yang ^a   Zhang, Yan ^b   Wu, Qunying ^c   Cui, Xuelian ^a   Lin, Zhenhua ^a   Liu, Shuangping ^a   Chen, Liyan ^a  

^a YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c Department of Pathology Yanbian Women and Children's Hospital   (China)

Author keywords

Breast cancer; Immunohistochemistry; NQO1; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAD(P)H QUINONE OXIDOREDUCTASE 1; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; CANCER PROGNOSIS; CANCER SURVIVAL; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MCF-7 CELLS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAD(P)H DEHYDROGENASE (QUINONE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 84893196764     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-14     Document Type: Article

References (29)

1. The role of targeted therapy and biomarkers in breast cancer treatment. Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS, Clin Exp Metastasis 2012 29 7 807 819 10.1007/s10585-012-9496-y 22692561
2. Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells. Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, Wagih M, Diaz-Arrastia C, Patel D, Salama S, J Cancer 2012 3 310 321 22866165
3. Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Thorat D, Sahu A, Behera R, Lohite K, Deshmukh S, Mane A, Karnik S, Doke S, Kundu GC, Oncol Lett 2013 6 6 1559 1564 24260046
4. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy inadvanced breast cancer. Camerini A, Donati S, Viacava P, Siclari O, Puccetti C, Tartarelli G, Valsuani C, De Luca F, Martini L, Cavazzana A, Amoroso D, J Exp Clin Cancer Res 2011 30 38 10.1186/1756-9966-30-38 21481270
5. Interplay of stem cell characteristics, EMT, and microtentacles in circulating breast tumor cells. Charpentier M, Martin S, Cancers 2013 5 1545 1565 10.3390/cancers5041545 24240660
6. Magnitude of risks and benefits ofthe addition of bevacizumab to chemotherapy for advanced breast cancerpatients: meta-regression analysis of randomized trials. Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F, J Exp Clin Cancer Res 2011 30 54 10.1186/1756-9966-30-54 21569417
7. NAD (P) H: quinone oxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: a meta-analysis. Zhu CL, Huang Q, Liu CH, Lin XS, Xie F, Shao F, Asian Pac J Cancer Prev 2013 14 4 2349 2354 10.7314/APJCP.2013.14.4.2349 23725139
8. NAD (P) H:quinine oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D, Chem Biol Interact 2000 129 77 97 10.1016/S0009-2797(00)00199-X 11154736
9. NAD (P) H:quinone oxidoreductase 1: role as a superoxide scavenger. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D, Mol Pharmacol 2004 65 1238 1247 10.1124/mol.65.5.1238 15102952
10. Qimuge-Suyila: NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia. Su XL, Yan MR, Yang L, Chin J Cancer Res 2012 24 4 317 322 10.1007/s11670-012-0270-0 23358185
11. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK, J Biol Chem 1998 273 7382 7389 10.1074/jbc.273.13.7382 9516435
12. The NAD (P) H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Garate M, Wani AA, Li G, Free Radic Biol Med 2010 48 1601 1609 10.1016/j.freeradbiomed.2010.03.003 20226854
13. Immunohistochemical detection of NAD (P) H:quinone oxidoreductase in human lung and lung tumors. Siegel D, Franklin WA, Ross D, Clin Cancer Res 1998 4 9 2065 2070 9748120
14. NQO1 Expression correlates with cholangiocarcinoma prognosis. Buranrat B, Chau-In S, Prawan A, Puapairoj A, Zeekpudsa P, Kukongviriyapan V, Asian Pac J Cancer Prev 2012 13 Suppl 131 136
15. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, Bentz JS, Shroyer KR, Appl Immunohistochem Mol Morphol 2008 16 24 31 18091324
16. NAD (P) H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Siegel D, Yan C, Ross D, Biochem Pharmacol 2012 83 8 1033 1040 10.1016/j.bcp.2011.12.017 22209713
17. Catalase abrogates β-lapachone-induced PARP1 hyperactivation- directed programmed necrosis in NQO1-positive breast cancers. Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA, Mol Cancer Ther 2013 12 10 2110 2120 10.1158/1535-7163.MCT-12- 0962 23883585
18. Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Jin J, Jin T, Quan M, Piao Y, Lin Z, Diagn Pathol 2012 7 135 10.1186/1746-1596-7-135 23039327
19. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. Liu S, Li L, Zhang Y, Zhao Y, You X, Lin Z, Zhang X, Ye L, J Biol Chem 2012 287 36 30228 30239 10.1074/jbc.M112.343947 22740693
20. High expression of ezrin predicts poor prognosis in uterine cervical cancer. Kong J, Li Y, Liu S, Jin H, Shang Y, Quan C, Li Y, Lin Z, BMC Cancer 2013 13 1 520 10.1186/1471-2407-13-520 24182314
21. Soluble diaphorase in animal tissues. Ernster L, Navazio F, Acta Chem Scand 1958 12 595
22. Increased levels of NAD (P) H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: a potential biomarker of early damage in the pancreas. Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons GJ, Cell Biol Toxicol 2006 22 73 80 10.1007/s10565-006-0156-3 16532285
23. The expression of NAD (P) H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas. Cheng Y, Li J, Martinka M, Li G, Oncol Rep 2010 23 4 973 979 20204281
24. Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population. Ouerhani S, Cherif N, Bahri I, Safra I, Menif S, Abbes S, Mol Biol Rep 2013 40 2 1307 1314 10.1007/s11033-012-2174-y 23065291
25. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide. Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE, Boddy AV, Pharmacogenet Genomics 2011 21 12 808 819 10.1097/FPC. 0b013e32834b6918 21946896
26. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Mikami K, Naito M, Ishiguro T, Yano H, Tomida A, Yamada T, Tanaka N, Shirakusa T, Tsuruo T, Jpn J Cancer Res 1998 89 910 915 10.1111/j.1349-7006.1998.tb00648.x 9818026
27. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, Au JL, Clin Cancer Res 2001 7 1313 1319 11350900
28. Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Lin L, Qin Y, Jin T, Liu S, Zhang S, Shen X, Lin Z, Exp Mol Pathol 2013 DOI: 10.1016 /j.yexmp. 2013.12.008
29. Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma. Wakai T, Shirai Y, Sakata J, Matsuda Y, Korita PV, Takamura M, Ajioka Y, Hatakeyama K, Int J Clin Exp Pathol 2011 4 4 363 370 21577322